Dr Reddy's On Digitization Amid COVID-19, 'Lights-Out' Manufacturing
Remote Inspections Were 'Good Learning'
Dr Reddy’s global head of quality outlines how the company leveraged digitization to keep plants running at full throttle amid the pandemic and went on to operationalize a site for remdesivir designed as a "lights out" facility. Certain facilities at the Indian firm have also undergone remote inspections by major regulatory agencies.
You may also be interested in...
Senior executives from Dr Reddy’s and Cipla showcase the “step-change” in performance across cost, quality and delivery metrics at their ‘lighthouse’ manufacturing sites in India as industry tackles dwindling operating margins and evolving compliance requirements.
The next chapter of Cipla’s innovation journey goes beyond its core respiratory thrust to include new platforms spanning areas such as peptides, where it has seen its first major approval in the US and has multiple programs lined up. Devices and diagnostics are among the other avenues being explored as the Indian company seeks to bring more patients into the “funnel”.
Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.